|
Synonyms: PBS-105 | PBS105
tuvonralimab is an approved drug
Compound class:
Antibody
Comment: Tuvonralimab (PBS105) is a humanized monoclonal antibody that targets the immune checkpoint protein, cytotoxic T-lymphocyte-associated protein 4 (CTLA4). It stimulates antitumour immunity.
|
| No information available. |
Summary of Clinical Use  |
| The Chinese drug regulator (NMPA) approved the bifunctional combination (MabPair™ Zimbab®; coded as PSB205 or QL1706) of (R)-DFV890 and tuvonralimab in October 2024, to treat recurrent or metastatic cervical cancer. The MabPair are produced together from a single cell line. Additional clinical studies will evaluate this dual therapy across various tumour types. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT06749899 | QL1706 (IPD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma. | Phase 3 Interventional | Sun Yat-sen University | ||
